Intravitreal Dexamethasone Implant (Ozurdex) for Refractory Macular Edema Secondary to Retinitis Pigmentosa | Zendy

Nurgül Örnek | Zendy; Kemal Örnek | Zendy; İnci Elif Erbahçeci | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Intravitreal Dexamethasone Implant (Ozurdex) for Refractory Macular Edema Secondary to Retinitis Pigmentosa

Author(s) -

Nurgül Örnek,

Kemal Örnek,

İnci Elif Erbahçeci

Publication year - 2016

Publication title -

turkish journal of ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.654

H-Index - 10

eISSN - 2147-2661

pISSN - 1300-0659

DOI - 10.4274/tjo.60437

Subject(s) - medicine , retinitis pigmentosa , dexamethasone , ophthalmology , visual acuity , triamcinolone acetonide , implant , refractory (planetary science) , acetazolamide , macular edema , surgery , retinal , anesthesia , physics , astrobiology

Macular edema (ME) in retinitis pigmentosa (RP) often impairs central vision dramatically. A 41-year-old woman diagnosed with RP was referred to our outpatient clinic due to severe visual deterioration in both eyes. The patient was treated with topical carbonic anhydrase inhibitors, topical corticosteroids and intravitreal triamcinolone acetonide injections, but her ME recurred. Intravitreal 0.7 mg dexamethasone implant (Ozurdex, Allergan) was administered into both eyes without complications. On the fourth day after both injections, visual acuity improved and ME almost totally resolved. No recurrence was observed at follow-up six months later.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research